 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 03, 2022 GLOBE NEWSWIRE -- Merus N.V. Nasdaq: MRUS, a clinical-stage oncology company developing innovative, full-length multispecific antibodies Biclonics and Triclonics, today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences: 